timothy sykes logo
Will VTAK’s Stock Climb Continue? Thumbnail
G Google News

Will VTAK’s Stock Climb Continue?

JACK KELLOGG•UPDATED AUG. 18, 2025, 9:19 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Catheter Precision Inc.’s stocks have been trading up by 68.58 percent amid promising FDA designations and positive sentiment.

Breakthroughs in Medical Technology

  • The innovative VIVO system by Catheter Precision has hit a milestone with 200 successful procedures at the Heart Hospital of New Mexico. This inspires confidence in cardiac care innovations.
  • Noteworthy progress as the first cases using LockeT in Germany have been completed. The device shows promise across varied sheath sizes, hinting at its wide-ranging application.
  • Revenue for Q2 for Catheter Precision saw a significant rise. It sky-rocketed to $212,000 from $93,000 last year, thanks to strategic moves and improved sales data, especially after the CE Mark for LockeT.

Candlestick Chart

Live Update At 09:18:28 EST: On Monday, August 18, 2025 Catheter Precision Inc. stock [NYSE American: VTAK] is trending up by 68.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview: Catheter Precision Inc.

“In the fast-paced world of trading, it’s essential to stay vigilant and responsive to market changes. As millionaire penny stock trader and teacher Tim Sykes says, ‘You must adapt to the market; the market will not adapt to you.’ This mindset is crucial for traders who wish to stay ahead, recognizing that flexibility and quick decision-making are key components of successful trading strategies.”

The financial landscape for Catheter Precision Inc. displays a roller coaster of figures. For the second quarter, revenue made a noticeable jump, signaling potential growth trajectory. However, translating these gains into net profit seems tricky. A significant point is the reversed fortune in the recent journey, where total expenses dipped into a significant negative value, trailing at $5M against earnings.

The financial backdrop features key ratios showing some instability. The profitability measures show considerable strain with ebbs and flows in profit margins. Meanwhile, the price-to-sales and book ratios appear grounded on reasonable footing. With a modest debt posture, the firm contests financial pressures effectively, albeit unevenly.

The stock’s journey remains intriguing, as reflected by its price oscillations over recent days. Several dips and peaks narrate a tale of the markets sifting through the company’s potential for future growth. Despite this seesaw, hope lives in projected prospects and underlying financial restructuring.

More Breaking News

The Ripple Effects of Recent News

The landscape for Catheter Precision’s stock is poised at a crucial juncture. Exciting news about the VIVO system and LockeT procedures establishes a cutting edge in cardiology, paving the way for expanded adoption. This innovation marks a compelling moment in tech advances, with doors to European markets widely opening.

Q2 earnings showed promising signs of a growing company grasping the reins of expansion. A robust trajectory should prove beneficial, yet it’s important not to ignore the upcoming reverse stock split. Stemming from a calculation change, the split could ruffle some investor feathers, sparking fresh excitement or doubt.

For those peering into Catheter Precision’s unfolding saga, awareness of these dynamics is essential. Enthusiastic believers might see this as a rallying cry for investment, while skeptics might regard it with a cautious side-eye. But one truth stands out: Curveballs, whether in innovations or financial gymnastics, demand sharp focus.

Conclusion: Navigating the Path Ahead

In sum, Catheter Precision Inc. is riding a wave of diversified developments. Strategic product launches and successful technological deployments boost the firm’s profile. Every financial nuance and breakthrough in medical tools paints a picture of a company carving out space in a competitive landscape. The stock’s path is fraught with potential and peril, a tapestry woven from a mix of promising innovations and financial juggling. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” This trading mantra rings true for those observing the twists and turns of the company. This tale, though yet unfinished, spins around the hope of sustainable success amid turbulent currents. Traders and stakeholders alike must weigh each move on the chessboard, as the future refines itself with every heartbeat of progress. For now, as VTAK navigates its journey, only time will crystalize its destiny.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”